6550.TW Overview

Company Profile

Polaris Group, together with its subsidiaries, offers biotechnology, pharmaceutical testing, and contract development and manufacturing services. The company engages in the research, development, manufacture and sale of new drugs. It also offers healthcare consulting, staffing, and MDS solutions. The company was incorporated in 2006 and is based in Grand Cayman, Cayman Islands.

Related stocks

456160.KQ

456160.KQ • South Korea

42,000 KRW

518.58M USD 1Y -37.2%

ALLO

ALLO • United States

Allogene Therapeutics, Inc.

1.46 USD

504.42M USD 1Y -4.8%

2617.HK

2617.HK • China

10.43 HKD

541.23M USD 1Y -92.1%

CBIO

CBIO • United States

Crescent Biopharma, Inc.

14.91 USD

553.86M USD 1Y +17.1%

476830.KQ

476830.KQ • South Korea

26,300 KRW

550.63M USD

005690.KS

005690.KS • South Korea

12,860 KRW

575.85M USD 1Y +4.7%

085660.KQ

085660.KQ • South Korea

8,200 KRW

568.93M USD 1Y -27.7%

1477.HK

1477.HK • China

5.08 HKD

517.26M USD 1Y -38.6%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile

5 Metrics

Country

Region

Sector

Industry

Website

https://www.polaris-group.com

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High

5Y Volatility

49.6% p.a.

Max Drawdown (5Y)

-96.2%

Sharpe Ratio (5Y)

-0.68

Beta Factor

0.59

Size Class

Mid Cap

Notes & Warnings

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).

Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (49.6% p.a.).

Historical Stress Test: Maximum peak-to-trough drawdown of -96.2% in the extended horizon.